26.15
+10.15%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Fulgent Genetics
From its filings with the US Securities and Exchange Commission
Fulgent Genetics is based in El Monte, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker FLGT. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $322.7m and a net loss of $60.5m. At that date it held total assets of $1.21bn and shareholders' equity of $1.11bn.
We are a technology-based company with a well-established laboratory services business and a therapeutic development business. Our laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Our therapeutic development business is focused on developing product candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs.
Founded in 2011, Fulgent began with two simple ideas: flexibility and affordability. We offer and develop flexible and affordable diagnostic and genetic tests and laboratory services designed to improve patient care and quality of life. We strive to provide the most effective and wide-ranging genetic and diagnostic testing menu on the market. Our long-term vision is to transform from a diagnostic business into a fully integrated precision medicine company.
Comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology. These services are supported by our expansive geographic presence with the Clinical Laboratory Improvement Amendments of 1988, or CLIA, licensed laboratories in the United States.
Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 28 Sept 2016
- Employees
- 1,300
- Website
- fulgentgenetics.com ↗
- Head office
- 4399 SANTA ANITA AVE, EL MONTE, CA, 91731
- Incorporated in
- DE
- Classification
- Services-Medical Laboratories
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Ming HsiehChairman of the Board, Chief Executive Officer, since 2016$6.1m
- Mr. Jian XiePresident, Chief Operating Officer$2.4m
- Mr. Paul KimChief Financial Officer$2.4m
- Dr. Hanlin GaoChief Scientific Officer, Laboratory Director$2.0m
- Ms. Regina GrovesIndependent Director$273,004
- Ms. Linda MarshIndependent Director$270,500
- Dr. Michael NohaileIndependent Director$268,500
- Ms. Melanie SolomonInvestor Relations, since 2022
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 57
- Environment
- 74
- Social
- 58
- Governance
- 39
- Direct emissions (scope 1)
- 576 t
- Energy emissions (scope 2)
- 3,953 t
- Women in the workforce
- 58%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Fulgent Genetics Inc has several key strengths that contribute to its success and competitive advantage in the market:
- Despite its strengths, Fulgent Genetics Inc faces certain weaknesses that may hinder its growth and performance in the market:
- Fulgent Genetics Inc can leverage various opportunities to further expand its business and market reach:
- Fulgent Genetics Inc must address potential threats that could impact its business and market position:
Weaknesses
- Despite its strengths, Fulgent Genetics Inc faces certain weaknesses that may hinder its growth and performance in the market:
- Fulgent Genetics Inc can leverage various opportunities to further expand its business and market reach:
- Fulgent Genetics Inc must address potential threats that could impact its business and market position:
Opportunities
- Fulgent Genetics Inc can leverage various opportunities to further expand its business and market reach:
- Fulgent Genetics Inc must address potential threats that could impact its business and market position:
Threats
- Fulgent Genetics Inc must address potential threats that could impact its business and market position:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.